UEG Week 2023

The place of IL-23 blockers in crohn's disease

New kids on the block - next generation therapeutics

Anti-TL1A: on the way to precision medicine?

Benefit of JAKies in ulcerative colitis

Do different JAKies have different profiles?

Is IL-23 blockade breaking the ceiling in UC?

Guselkumab readily controls symptoms in patients affected by UC: results from the QUASAR study

Key topic S1P-modulation

News on IBD therapy!

Small molecules in IBD

Update on JAKies

A lot of noise about IL-23 blockers - 1

A lot of noise about IL-23 blockers - 2

Novità nelle terapie per le IBD!

S1P-Modulatoren im Fokus

Update zu JAK-Inhibitoren

Viel Wirbel um die Interleukin-23-Blockade

Rapido controllo dei sintomi nei pazienti affetti da RCU in trattamento con Guselkumab: risultati dallo studio QUASAR

Small molecules nelle IBD

Mirikizumab reaches similar therapeutic outcomes in UC irrespective of prior exposure to advanced therapies.

Head-to-head efficacy comparison of risankizumab vs ustekinumab in CD refractory to anti-TNF: results from the sequence trial

Long-term efficacy of obefazimod in UC

Ustekinumab vs. adamlimumab for prevention of early post-operative recurrence in CD

First positive head-to-head trial in CD

Risankizumab vs. ustekinumab in CD: The SEQUENCE trial

Phase III results of filgotinib in CD

High IL23 expression at baseline is predictive of clinical remission and endoscopic response in CD patients treated with risankizumab

Elevati livelli basali di IL23 predicono la remissione clinica e la risposta endoscopica in pazienti affetti da MDC trattati con Risankizumab

Comparazione testa a testa di Risankizumab e Ustekinumab in pazienti refrattari a terapia con anti-TNF: risultati dallo studio sequence

Ustekinumab vs. adalimumab για την πρόληψη της πρώιμης μετεγχειρητικής ενδοσκοπικής υποτροπής της νόσου του Crohn

Mirikizumab resulta efficace in RCU a prescindere dalla precedente esposizione a terapie avanzate.

Mirikizumab in moderate to severe UC

Risankizumab in UC

Longterm endohistological response induced by mirikizumab in UC patients

Disease clearance induced by etrasimod and relationship between disease clearance and clinical outcome

Another p19 antibody in UC

PRA023 - a new anti-TL1A antibody in moderate to severe UC

Fast-acting etrasimod in UC

Disease severity affects response in ozanimod treated pts.

PRA023 - un nuovo anticorpo anti-TL1A nella colite ulcerosa da moderata a grave

Lange termijn efficaciteit van Obefazimod UC

Fase III resultaten met filgotinib in CD

Mirikizumab nella colite ulcerosa da moderata a grave

S1P modulation: ozanimod vs. etrasimod

Can we stop biologics?

Combined endpoints - composition and implementation in daily practice

Efficacy and safety of switching iv vs. sc

How to prevent post-operative recurrence in CD?

The quest for perfect predictors of response - AI entering the stage

Navigating in the therapeutic IBD landscape

To switch or not to switch in IBD - new real-life data already available

Infliximab sc application associated with better treatment persistence

More evidence that anti TNF-withdrawel increases relapse

Navigeren in het therapeutisch landschap in IBD

Konwersja do terapii podskórnej NZJ - nowe dane typu real-life

Infliximab sc führt zu besseren Langzeitergebnissen

Did GETAID close the window of opportunity?

Stopping adalimumab in early CD?

Surgical news: prevention of post-operative recurrence in crohn's disease

SEQUENCE study

Postoperative recurrence in Crohn's disease after ileocecal resection - the PORCSE study

Medical news: Which treatment and when?

Actualités médicales: Quel traitement et quand?

Nawroty pooperacyjne u pacjentów z chorobą Leśniowskiego-Crohna po resekcji ileocekalnej - badanie PORCSE

Nouveauté sur la chirurgie: Prévention de la récidive post-opératoire dans la maladie de Crohn

Peut-on arrêter l'adalimumab dans la maladie de Crohn précoce?

SEQUENCE Studie

Hat GETAID das "Window of opportunity" geschlossen?

The anti TL1A/Dx-toolbox package: Are we entering precision medicine?

Which maintenance therapy in AS-CU is responding to steroids?

Quel traitement d'entretien dans l'AS-CU répondant aux stéroïdes?

Anti-TL1A im Paket mit der Dx-Toolbox - Einstieg in die Präzisionsmedizin?

Comprehensive disease control - a new currency

Comprehensive disease control - eine neue Währung

What do we know about multi-failures?

S1P modulation: effective and safe?

New safety signals on JAKies?

Is it feasible to stop effective anti-TNF therapy in IBD? The GETECCU RCT

Do JAK inhibitors cause acne?

Effective control of EIMs in CD patients treated with risankizumab

Is risankinumab effective for EIMs of IBD?

Czy możemy bezpiecznie przerwać skuteczną terapię anty-TNF w NZJ - wyniki badania grupy GETECCU

Προκαλούν οι αναστολείς των JAK ακμή;

Είναι το risankisumab αποτελεσματικό για τη θεραπεία των εξωεντερικών εκδηλώσεων των ΙΦΝΕ;

Efficace controllo delle MEI in pazienti affetti da MDC trattati con Risankizumab

Morphologic alteration of mesentric lymph nodes under ozanimod

Neutrophil fibroblast crosstalk is driving fribrosis in CD

Morphologische Veränderung mesenterialer Lymphknoten unter Ozanimod

Neutrophile Fibroblasteninteraktion treibt die Fibrose bei Morbus Crohn